A Study of Ruxolitinib in Patients With Graft-Versus Host Disease

Recruiting now

Conditions studied: Graft-Versus-Host Disease

In brief

This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.

Key facts

Study ID

NCT07594587

Run by

Novartis Pharmaceuticals

People needed

395

Starts

2026-05-11

Expected to finish

2030-05-15

Last updated by the study team

2026-06-08

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with acute and chronic GVHD
• Patients treated with ruxolitinib

You may not qualify if…

• None
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis — Tokyo, Japan (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.